AbbVie, Alvotech settle Humira patent and trade secrets disputes, teeing up another biosim rollout next yearnews2022-03-09T14:30:54+00:00March 9th, 2022|Fierce Pharma|
That key Gilead breast cancer readout? Try 2024, and don’t get your hopes up: analystnews2022-03-09T14:26:36+00:00March 9th, 2022|Fierce Pharma|
Mallinckrodt inks $260M settlement with US to resolve Medicaid underpayment and kickbacks allegationsnews2022-03-08T21:52:26+00:00March 8th, 2022|Fierce Pharma|
Pressing for label change, vaccine giant Sanofi takes Seqirus influenza imbroglio to the FDAnews2022-03-08T20:05:08+00:00March 8th, 2022|Fierce Pharma|
With J&J-partnered CAR-T nod in hand, Legend CEO eyes earlier myeloma use, cheaper cell therapy manufacturingnews2022-03-08T15:51:41+00:00March 8th, 2022|Fierce Pharma|
Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquartersnews2022-03-08T15:48:31+00:00March 8th, 2022|Fierce Pharma|
J&J says it regrets injecting prisoners with asbestos, but such experiments were ‘widely accepted’ at the timenews2022-03-08T15:15:13+00:00March 8th, 2022|Fierce Pharma|
Moderna will provide access to mRNA tech, but high-income countries will have to paynews2022-03-08T14:43:48+00:00March 8th, 2022|Fierce Pharma|
Mass General plans study of nasally delivered binge eating disorder drugnews2022-03-08T13:50:00+00:00March 8th, 2022|Fierce Pharma|
FDA accelerated approvals targeted for revamp in House Energy and Commerce committee chair’s new billnews2022-03-08T13:43:47+00:00March 8th, 2022|Fierce Pharma|
